Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Richard Pratley MD
Richard E. Pratley MD Associate Editor
Deborah Wexler MD, MSc
Deborah J. Wexler MD, MSc Associate Editor
Kathleen Dungan MD, MPH
Kathleen M. Dungan MD, MPH Advisory Board
See All Experts
featured
Published in Diabetes and
1 other channel

Journal Scan / Research · November 03, 2015

DPP-4 Inhibitors vs Sulfonylureas With Metformin in Type 2 Diabetes Mellitus

Annals of Internal Medicine

 

 Save  Recommend
 Share

Additional Info

Disclosure statements are available on the authors' profiles:

Silvio Inzucchi MD

Annals of Internal Medicine
Effects on Clinical Outcomes of Adding Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas to Metformin Therapy in Patients With Type 2 Diabetes Mellitus
Ann. Intern. Med 2015 Oct 13;[EPub Ahead of Print], SM Ou, CJ Shih, PW Chao, H Chu, SC Kuo, YJ Lee, SJ Wang, CY Yang, CC Lin, TJ Chen, DC Tarng, SY Li, YT Chen

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading

Most Read This Week

Recently Updated